20/20 Biolabs Secures 12‑Month Stand‑Still with Streeterville Capital on Series E Preferred Shares
20/20 Biolabs inks a 12‑month stand‑still with Streeterville Capital, safeguarding share stability while pushing AI‑powered cancer and longevity tests toward market launch.
3 minutes to read